"IS THERE A MORTALITY BENEFIT WITH RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IN AFRICAN AMERICANS (AA) WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)?" by Ravinder R. Valadri

Article

IS THERE A MORTALITY BENEFIT WITH RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IN AFRICAN AMERICANS (AA) WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)?

Journal of the American College of Cardiology (2012)

Ravinder R. Valadri, Emory University
Emir Veledar, Emory University
radhika gadesam, Emory University
Saumeth Cardona, Emory University
Jo Ann Cross, Emory University
Gregory Strayhorn, Emory University
Heather Bloom, Emory University
Adefisayo Oduwole, Emory University
David De Lurgio, Emory University
Javed Butler, Emory University
Elizabeth Ofili, Emory University
Anekwe Onwuanyi, Emory University

Link

Disciplines

Publication Date

January 3, 2012

DOI

10.1016/S0735-1097(12)60961-9

Citation Information

Ravinder R. Valadri, Emir Veledar, radhika gadesam, Saumeth Cardona, et al.. "IS THERE A MORTALITY BENEFIT WITH RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IN AFRICAN AMERICANS (AA) WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)?" Journal of the American College of Cardiology Vol. 59 Iss. 13 (2012)
Available at: http://works.bepress.com/emir-veledar/323/